Showing 4721-4730 of 7240 results for "".
- AAD Updates Systemic Therapy Guidelines for Adult ADhttps://practicaldermatology.com/news/aad-updates-systemic-therapy-guidelines-for-adult-atopic-dermatitis/2486418/The American Academy of Dermatology (AAD) has issued an interim update to its clinical practice guidelines for systemic treatment of moderate to severe atopic dermatitis (AD) in adults, reflecting the rapid expansion of evidence supporting targeted therapies. The u
- GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areatahttps://practicaldermatology.com/news/glp-1-receptor-agonists-show-complex-evolving-role-in-alopecia-areata/2486415/The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meet
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.
- New Grants Expand Teledermatology Access in the Bronx and Los Angeleshttps://practicaldermatology.com/news/new-gwpfizer-grants-expand-teledermatology-access-in-the-bronx-and-los-angeles/2486357/The George Washington University School of Medicine (GW) and Health Sciences, in collaboration with Pfizer Global Medical Grants, has awarded 2 new grants to expand teledermatology services in underserved US communities, with 2026 programs set for the Bronx and Los
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- BE BOLD: Bimekizumab Shows Superiority Over IL-23 Inhibitor in Psoriatic Arthritishttps://practicaldermatology.com/news/be-bold-trial-bimekizumab-shows-superiority-over-il-23-inhibitor-in-psoriatic-arthritis/2486038/Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity at Week 16 in adults with active psoriatic arthritis (PsA), according to topline results from the phase 3 BE BOLD head-to-head trial announced by UCB.
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://practicaldermatology.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo
- Most Nations Off Track to Meet 2030 Skin NTD SDG Targets: Reporthttps://practicaldermatology.com/news/most-nations-off-track-to-meet-2030-skin-ntd-sdg-targets-report/2485823/A new report in JAMA Dermatology revealed that most countries are unlikely to achieve the World Health Organization (WHO) target of a 75% reduction in disability-adjusted life-years (DALYs) from skin-related neglected tropical diseases (NTDs) from 2020 lev
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.